Wes Brazell is the Chief Financial Officer of Xequel Bio. Wes leads Xequel’s financial, information technology, and legal functions, including financial reporting, planning, corporate finance, investor relations, and compliance.
Wes brings over 30 years of experience in life sciences, with varied experiences in financial management, business development, international operations, and corporate strategy. Prior to joining Xequel, Wes was the Chief Financial Officer of Eyevance Pharmaceuticals, a Private Equity backed venture established in 2017 and acquired by Santen, Ltd. in 2020. Prior to Eyevance, Wes was the Chief Financial Officer of TearLab Corporation, a NASDAQ listed company focused on the marketing and development of tear film diagnostic products. In addition, Wes spent 21 years with Alcon, a global leader in ophthalmic pharmaceuticals, medical device, and over-the-counter products, where he held a variety of financial leadership roles including Vice-President of Finance for the U.S region, Vice-President of Finance for the Europe, Middle East and Africa region, and Vice-President of Global Business Planning and Analysis.
His favorite thing about Xequel Bio is working in an entrepreneurial team environment with incredible energy, passion, and focus on bringing new technologies to patients, as well as the reward of seeing these technologies grow and flourish. Wes is a history buff who enjoys music and water sports in his spare time.